TrialClinical research in cardiology : official journal of the German Cardiac Society2023

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.

Julie Kolwelter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.